Xin Lang Cai Jing·2025-08-28 02:45Group 1 - The stock price of Zhaoyan New Drug fell by 5.53% on August 28, closing at 30.21 yuan per share, with a trading volume of 408 million yuan and a turnover rate of 2.08%, resulting in a total market capitalization of 22.642 billion yuan [1] - Zhaoyan New Drug Research Center Co., Ltd. is located in Beijing and was established on February 25, 1998. The company went public on August 25, 2017, and primarily engages in non-clinical safety evaluation services for drugs and the sale of experimental animals and related products [1] Group 2 - According to data, one fund under Rongtong Fund holds a significant position in Zhaoyan New Drug. The Rongtong Healthcare Industry Mixed A/B Fund (161616) held 1.2568 million shares in the second quarter, accounting for 3.25% of the fund's net value, ranking as the tenth largest holding [2] - The Rongtong Healthcare Industry Mixed A/B Fund was established on July 26, 2012, with a current scale of 660 million yuan. Year-to-date, it has achieved a return of 18.22%, ranking 3780 out of 8190 in its category, and a one-year return of 31.5%, ranking 4228 out of 7966 [2] - The fund managers, Wan Minyuan and Liu Xiyang, have different tenures and performance records. Wan Minyuan has a tenure of 9 years and 5 days, managing assets totaling 4.223 billion yuan, with the best return of 156.05% and the worst return of -17.58% during his tenure. Liu Xiyang has been managing 814 million yuan for 1 year and 167 days, with a best return of 1.41% and a worst return of 0.98% [2]